Terms: = Ovarian cancer AND RET, RET51, 5979, P07949, ENSG00000165731, MTC1, MEN2A, RET-ELE1, HSCR1, MEN2B, CDHF12
47 results:
1.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract] [Full Text] [Related]
2. FDA Approval Summary: Selpercatinib for the Treatment of Advanced ret Fusion-Positive Solid Tumors.
Duke ES; Bradford D; Marcovitz M; Amatya AK; Mishra-Kalyani PS; Nguyen E; Price LSL; Fourie Zirkelbach J; Li Y; Bi Y; Kraft J; Dorff SE; Scepura B; Stephenson M; Ojofeitimi I; Nair A; Han Y; Tezak Z; Lemery SJ; Pazdur R; Larkins E; Singh H
Clin Cancer Res; 2023 Sep; 29(18):3573-3578. PubMed ID: 37265412
[TBL] [Abstract] [Full Text] [Related]
3. Cystic ovarian teratoma as a novel tumor and growth hormone deficiency as a new condition presenting in Multiple Endocrine Neoplasia type 2B: Case reports and review of the literature.
Pomahacova R; Paterova P; Nykodymova E; Vaclavikova E; Sykorova P; Personova K; Katra R; Subrt I; Sykora J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2022 Mar; 166(1):105-111. PubMed ID: 34446941
[TBL] [Abstract] [Full Text] [Related]
4. ARID1A genomic alterations driving microsatellite instability through somatic MLH1 methylation with response to immunotherapy in metastatic lung adenocarcinoma: a case report.
Durán M; Faull I; Lastra E; Laes JF; Rodrigo AB; Sánchez-Escribano R
J Med Case Rep; 2021 Feb; 15(1):89. PubMed ID: 33608032
[TBL] [Abstract] [Full Text] [Related]
5. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast cancer or ovarian cancer, 2012-2019.
Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
[TBL] [Abstract] [Full Text] [Related]
6. Preimplantation Genetic Testing of Multiple Endocrine Neoplasia Type 2A.
Würgler Hansen A; Sønderberg Roos LK; Løssl K; Godballe C; Mathiesen JS
Front Endocrinol (Lausanne); 2020; 11():572151. PubMed ID: 33178136
[No Abstract] [Full Text] [Related]
7. Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations.
Poli R; Scatolini M; Grosso E; Maletta F; Gallo M; Liscia D; Nelva A; Cesario F; Forte G; Metovic J; Volante M; Arvat E; Papotti M
Endocrine; 2021 Jan; 71(1):216-224. PubMed ID: 32743766
[TBL] [Abstract] [Full Text] [Related]
8. CHEK2 Mutation in Patient with Multiple Endocrine Glands Tumors. Case Report.
Szeliga A; Pralat A; Witczak W; Podfigurna A; Wojtyla C; Kostrzak A; Meczekalski B
Int J Environ Res Public Health; 2020 Jun; 17(12):. PubMed ID: 32570972
[TBL] [Abstract] [Full Text] [Related]
9. Oncogenic and drug-sensitive ret mutations in human epithelial ovarian cancer.
Guan L; Li Z; Xie F; Pang Y; Zhang C; Tang H; Zhang H; Chen C; Zhan Y; Zhao T; Jiang H; Jia X; Wang Y; Lu Y
J Exp Clin Cancer Res; 2020 Mar; 39(1):53. PubMed ID: 32293499
[TBL] [Abstract] [Full Text] [Related]
10. Tyrosine kinase inhibitors vandetanib, lenvatinib and cabozantinib modulate oxidation of an anticancer agent ellipticine catalyzed by cytochromes P450 in vitro.
Kolarik M; Indra R; Adam V; Heger Z; Kopeckova K; Arlt VM; Stiborova M
Neuro Endocrinol Lett; 2019 Feb; 39(7):515-524. PubMed ID: 30860683
[TBL] [Abstract] [Full Text] [Related]
11. A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
Matulonis UA; Sill MW; Makker V; Mutch DG; Carlson JW; Darus CJ; Mannel RS; Bender DP; Crane EK; Aghajanian C
Gynecol Oncol; 2019 Mar; 152(3):548-553. PubMed ID: 30587441
[TBL] [Abstract] [Full Text] [Related]
12. Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours.
Schöffski P; Gordon M; Smith DC; Kurzrock R; Daud A; Vogelzang NJ; Lee Y; Scheffold C; Shapiro GI
Eur J Cancer; 2017 Nov; 86():296-304. PubMed ID: 29059635
[TBL] [Abstract] [Full Text] [Related]
13. Serous versus high-grade endometrioid endometrial carcinoma: immunohistochemistry of RFP is not useful for differentiation.
Ussakli C; Usubutun A; Dincer N; Dolgun A; Bülbül D; Isikdogan Z; Haberal N; Ozen O; Tezel GG
Pol J Pathol; 2016; 67(3):221-227. PubMed ID: 28155970
[TBL] [Abstract] [Full Text] [Related]
14. Clinical evaluation of MRI in the differential diagnosis between benign and malignant ovarian tumors.
Zhang T; Yi X; Lu J; Fu A
Eur J Gynaecol Oncol; 2017; 38(2):257-262. PubMed ID: 29953791
[TBL] [Abstract] [Full Text] [Related]
15. Screening for germline mutations in breast/ovarian cancer susceptibility genes in high-risk families in Israel.
Yablonski-Peretz T; Paluch-Shimon S; Gutman LS; Kaplan Y; Dvir A; Barnes-Kedar I; Kadouri L; Semenisty V; Efrat N; Neiman V; Glasser Y; Michaelson-Cohen R; Katz L; Kaufman B; Golan T; Reish O; Hubert A; Safra T; Yaron Y; Friedman E
Breast Cancer Res Treat; 2016 Jan; 155(1):133-8. PubMed ID: 26687385
[TBL] [Abstract] [Full Text] [Related]
16. Downregulation of TRIM27 expression inhibits the proliferation of ovarian cancer cells in vitro and in vivo.
Ma Y; Wei Z; Bast RC; Wang Z; Li Y; Gao M; Liu Y; Wang X; Guo C; Zhang L; Wang X
Lab Invest; 2016 Jan; 96(1):37-48. PubMed ID: 26568293
[TBL] [Abstract] [Full Text] [Related]
17. Identification of rare germline copy number variations over-represented in five human cancer types.
Park RW; Kim TM; Kasif S; Park PJ
Mol Cancer; 2015 Feb; 14():25. PubMed ID: 25644941
[TBL] [Abstract] [Full Text] [Related]
18. The cl2/dro1/ccdc80 null mice develop thyroid and ovarian neoplasias.
Leone V; Ferraro A; Schepis F; Federico A; Sepe R; Arra C; Langella C; Palma G; De Lorenzo C; Troncone G; Masciullo V; Scambia G; Fusco A; Pallante P
Cancer Lett; 2015 Feb; 357(2):535-41. PubMed ID: 25497869
[TBL] [Abstract] [Full Text] [Related]
19. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract] [Full Text] [Related]
20. The immunohistochemical profile of granular cell (Abrikossoff) tumor suggests an endomesenchymal origin.
Gurzu S; Ciortea D; Tamasi A; Golea M; Bodi A; Sahlean DI; Kovecsi A; Jung I
Arch Dermatol Res; 2015 Mar; 307(2):151-7. PubMed ID: 25262119
[TBL] [Abstract] [Full Text] [Related]
[Next]
